Specialized Medical Reports SAR 32.55M Net Profit in Three Months 2026
SMC HEALTHCARE 4019.SA | 0.00 |
On 2026-05-06 08:14:59 (Saudi Time), Specialized Medical Co. announced its Interim financial results for the three months ended on March 31, 2026.
| Element List | Current Quarter | Similar quarter for previous year | %Change | Previous Quarter | % Change |
|---|---|---|---|---|---|
| Sales/Revenue | 380,674 | 368,396 | 3.332 | 406,908 | -6.447 |
| Gross Profit (Loss) | 90,968 | 88,417 | 2.885 | 84,906 | 7.139 |
| Operational Profit (Loss) | 41,083 | 40,675 | 1.003 | 80,199 | -48.773 |
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 32,550 | 29,640 | 9.817 | 133,980 | -75.705 |
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 31,101 | 29,268 | 6.262 | 129,627 | -76.007 |
| All figures are in (Thousands) Saudi Arabia, Riyals | |||||
| Element List | Current Period | Similar period for previous year | %Change |
|---|---|---|---|
| Total Shareholders Equity (after Deducting Minority Equity) | 1,018,954 | 856,363 | 18.986 |
| Profit (Loss) per Share | 0.13 | 0.12 | |
| All figures are in (Thousands) Saudi Arabia, Riyals | |||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Thousands) Saudi Arabia, Riyals | |||
Year-on-Year Performance Drivers
Sales increased 3.332% YoY to 380.67 million SAR, driven by increased outpatient clinic activity from 57 new clinics opened in 2025 and higher inpatient revenues from a strategic shift to higher-margin acute care services, despite seasonal impacts from extended school breaks and Eid al-Fitr holidays. Net profit rose 9.817% YoY to 32.55 million SAR with net profit margin expanding to 8.6% from 8.0%, primarily due to revenue growth combined with reduced selling and marketing expenses and lower finance costs.
Quarter-on-Quarter Performance Drivers
QoQ revenue declined 6.4% to SAR 380.67 million due to seasonal impacts from extended school breaks and Eid al-Fitr holidays, which reduced patient volumes and elective procedures. Net profit dropped 75.7% to SAR 32.55 million, primarily driven by the revenue decline and the absence of a one-off SAR 60.6 million gain from land sale that boosted Q4 2025 results.
Other Items
The auditors issued an unmodified conclusion for the interim financial statements. Total shareholders equity increased 18.986% to SAR 1,018,954 thousand compared to the same period last year. Earnings per share improved to SAR 0.13 from SAR 0.12 in the prior year period. EBITDA reached SAR 69.3 million with a margin of 18.2% compared to 17.8% in Q1 2025. Certain comparative figures were reclassified to conform to current period presentation.
Original announcement:
https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anId=94988&anCat=1&cs=4019&locale=arAttached PDF document link:
https://www.saudiexchange.sa/Resources/fsPdf/27595_7686_2026-05-05_18-05-08_en.pdfImportant Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.